Hepatocellular Carcinoma | Specialty

Dr Kim on the CARES-310 Study of Rivoceranib Plus Camrelizumab in First-Line HCC

November 19th 2024

Richard Kim, MD, discusses the phase 3 CARES-310 trial evaluating rivoceranib plus camrelizumab in first-line hepatocellular carcinoma.

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

November 7th 2024

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

Building Upon Approved Combination Regimens in Unresectable HCC

October 28th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.

The STRIDE Regimen vs Atezolizumab/Bevacizumab: Selecting a Treatment Regimen in Unresectable HCC

October 25th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.

5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC

October 25th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.

FDA Accepts NDA Resubmission for First-Line Rivoceranib/Camrelizumab Combo in Unresectable HCC

October 21st 2024

The FDA has accepted the new drug application resubmission for the first-line combination of rivoceranib plus camrelizumab in unresectable HCC.

Dr Llovet on the Efficacy of TACE With or Without Lenvatinib Plus Pembrolizumab in HCC

October 7th 2024

Josep Llovet, MD, discusses the effiacy of TACE treatment with or without lenvatinib plus pembrolizumab in intermediate-stage hepatocellular carcinoma.

NDA Resubmitted for Camrelizumab Plus Rivoceranib in Unresectable HCC

September 23rd 2024

An NDA seeking the approval of camrelizumab plus rivoceranib for the frontline treatment of patients with unresectable HCC has been resubmitted to the FDA.

Durvalumab/Tremelimumab Sustains OS Benefit in Unresectable HCC

September 16th 2024

Tremelimumab plus durvalumab sustained an overall survival improvement in unresectable hepatocellular carcinoma.

TACE Plus Lenvatinib and Pembrolizumab Improves PFS in Intermediate-Stage HCC

September 14th 2024

Lenvatinib, pembrolizumab, and TACE improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma.

FDA Approves Subcutaneous Atezolizumab and Hyaluronidase-tqjs for Use in All Indications of IV Atezolizumab

September 12th 2024

The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.

Dr El-Khoueiry on Immune Suppression in Advanced HCC After Checkpoint Inhibitors

August 27th 2024

Anthony B. El-Khoueiry, MD, discusses immune suppression in advanced hepatocellular carcinoma post-checkpoint inhibitor therapy.

Atezolizumab/Bevacizumab Represents Potential Therapeutic Option in Child-Pugh B7 HCC

August 12th 2024

Atezolizumab plus bevacizumab showed efficacy in patients with hepatocellular carcinoma who had Child-Pugh B7 liver function.

CIRT Plus Durvalumab/Tremelimumab Is Safe in Advanced HCC With Macrovascular Invasion

August 8th 2024

CIRT plus durvalumab and tremelimumab was safe in patients with advanced hepatocellular carcinoma with macrovascular invasion.

EMA Grants Orphan Medicinal Product Designation to Rivoceranib/Camrelizumab in First-Line Unresectable HCC

August 1st 2024

The EMA has granted orphan medicinal product designation to rivoceranib plus camrelizumab in first-line unresectable hepatocellular carcinoma.

Two Leading Experts Detail Hot Topics in GI Cancers to Be Presented at Upcoming ISGIO Meeting

July 31st 2024

Eileen M. O’Reilly, MD, and Tanios S. Bekaii-Saab, MD, FACP, discuss key topics in gastrointestinal cancer to be presented during the 2024 ISGIO Meeting.

Dr Franses on the Need for Prospective Data in Second-Line HCC and Beyond

July 23rd 2024

Joseph Franses, MD, PhD, discusses the need for more prospective data in the second-line setting and beyond for patients with hepatocellular carcinoma.

Dr Franses on Considerations for Second-Line Treatment of HCC

July 19th 2024

Joseph Franses, MD, PhD, discusses treatment considerations for hepatocellular carcinoma that progresses after first-line therapy.

Complexity in GI Cancer: Questions Are Answered in Gastroesophageal Cancer, Remain in HCC

July 19th 2024

Tanios S. Bekaii-Saab, MD, FACP, details data from the ESOPEC trial in early-stage gastroesophageal cancers, and findings from Checkmate-9DW in HCC.

EMA Validates Application for Nivolumab Plus Ipilimumab in Frontline HCC

July 19th 2024

The type II variation application for frontline nivolumab plus ipilimumab in unresectable/advanced hepatocellular carcinoma was validated by the EMA.